They must demonstrate the ability to manufacture and distribute the drug or the FDA just won't approve it. It's as simple as that.
Jon said at the AGM the 2591 commercial product is being made now and will be ready for phase 3 trials. He also said the gap between phase 2 and 3 trials will be much shorter than for Daybue and proceedings will start after the terms are determined with the FDA in this quarter's meeting.
In my opinion, Neuren is prepared for any eventuality whether it be your suggestion or a takeover.
- Forums
- ASX - By Stock
- NEU
- Possibly a new direction?
Possibly a new direction?, page-26
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.61 |
Change
0.010(0.06%) |
Mkt cap ! $1.995B |
Open | High | Low | Value | Volume |
$15.64 | $15.93 | $15.44 | $8.412M | 538.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 558 | $15.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.66 | 1841 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 558 | 15.590 |
1 | 100 | 15.580 |
1 | 64 | 15.550 |
1 | 3405 | 15.520 |
3 | 3288 | 15.510 |
Price($) | Vol. | No. |
---|---|---|
15.660 | 1841 | 1 |
15.680 | 1447 | 2 |
15.690 | 1841 | 1 |
15.720 | 1841 | 1 |
15.730 | 2500 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online